{"id":"W2577775436","doi":"10.1136/jnnp-2016-315106.144","title":"OCRELIZUMAB VS INTERFERON β-1A IN RELAPSING MS: TWO STUDIES","year":2016,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; McGill University; NeuroRx Research (Canada)","funders":"","keywords":"Ocrelizumab; Medicine; Clinical endpoint; Opera; Adverse effect; Internal medicine; Interferon beta-1a; Monoclonal; Monoclonal antibody; Gastroenterology; Interferon; Clinical trial; Immunology; Antibody; Interferon beta; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008235849,0.001557251,0.004986505,0.0006821143,0.0004821187,0.001891672,0.000955152,0.003001726,0.005694324],"category_scores_gemma":[0.007369641,0.0006795239,0.00827546,0.0009940156,0.000804836,0.0009302142,0.0006865685,0.002108329,0.0006469646],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001112631,"about_ca_system_score_gemma":0.001636943,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001701594,"about_ca_topic_score_gemma":0.003384463,"domain_scores_codex":[0.9969462,0.001753672,0.0004724811,0.0002935529,0.0003099313,0.0002241552],"domain_scores_gemma":[0.9920475,0.004311054,0.001824013,0.0005905963,0.0005527937,0.0006739587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.8627796,0.002912077,0.001668474,0.02089232,0.02672335,0.0002295461,0.0002544869,0.0003009368,0.004930891,0.0002370541,0.00111837,0.07795282],"study_design_scores_gemma":[0.7440287,0.1473814,0.0160654,0.004766131,0.07428481,0.0004984064,0.0002443357,0.0004064368,0.001729488,0.0006593734,0.009830347,0.0001051438],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5447534,0.4364857,0.001577901,0.002615831,0.001448433,0.004333235,0.002068457,0.0001239175,0.0065932],"genre_scores_gemma":[0.8747228,0.1132423,0.001637187,0.002860627,0.001856732,0.002095042,0.001484375,0.00004284309,0.002058024],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008235849,"threshold_uncertainty_score":0.0435558,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04102727807022322,"score_gpt":0.3591835231633255,"score_spread":0.3181562450931023,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}